Levosimedan improves hemodynamics functions without sympathetic activation in severe XXXX @entity1 : direct evidence from sympathetic neural recording.

@entity1 @entity712 @entity452 @entity64 @entity460 @entity6759
@entity6759 is a new inodilatory agent with @entity460 sensitizing activity. A major concern regarding the use of inotropic agent in @entity712 is their effect on the sympathetic tone. This effect could explain increase in short term mortality with other inotropes. We aimed to assess the effect of @entity6759 on sympathetic tone measured directly by microneurogra-phy. In a group of acute decompensated @entity712 @entity1 , we assessed cardiac performance by digital plethysmography measurement. Sympathetic tone was assessed through recording of muscle sympathetic nerve activity (MSNA) by micro-neurography. Recording were done blindly, for each @entity1 after @entity452 perfusion was stopped (baseline) and 48 h after @entity6759 infusion. Clinical, biological and morphological data were collected. We compared cardiac parameters and MSNA before and after administration of @entity6759 . 13 @entity1 were recruited (48 +/- 3.6 years). Systolic blood pressure and rate pressure product (mmHg x Beat/min) decreased significantly after @entity6759 infusion (P< 0.05). Cardiac output and @entity64 volume were significantly increased after @entity6759 infusion (P< 0.05). A significant decrease of MSNA activity is observed after @entity6759 infusion (P< 0.01). @entity6759 induced improvement of cardiac performance, associated with a decreased in MSNA. This study show for the first time that @entity6759 has no direct detrimental effect on the sympathetic nervous system.
